胺基醣苷類抗生素市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球胺基醣苷類抗生素市值為 19 億美元，預計 2025 年至 2034 年期間的複合年成長率為 4%。它們廣泛應用於治療泌尿道感染、肺炎和敗血症等疾病，凸顯了它們在現代醫療保健中的重要作用。這些抗生素是抵抗細菌感染的基石，特別是在其他治療方法可能失敗的情況下。它們的多功能性以及抗菌素抗藥性的日益普遍進一步鞏固了它們在全球市場的需求。

世界各國政府將這些基本抗生素納入補貼醫療保健系統和國家計劃，為胺基醣苷類抗生素市場的成長做出了重大貢獻。這不僅提高了可近性，而且確保了它們可用於管理各種傳染病。此外，靜脈給藥吸入溶液等先進劑型的開發和採用擴大了其在治療支氣管疾病中的應用，從而增加了對胺基醣苷類抗生素的需求。

市場依產品細分為新黴素、妥布黴素、慶大霉素、阿米卡星、巴龍黴素、鏈黴素及其他產品。 2024 年，慶大霉素成為領先市場，市場估值達 5.416 億美元。抗藥性細菌感染的日益普及增加了人們對慶大霉素等強效抗生素的依賴。隨著抗菌素抗藥性持續挑戰全球醫療保健格局，慶大霉素的功效使其成為醫療保健專業人士的首選。

從應用角度來看，胺基醣苷類抗生素市場分為細菌感染、結核病和其他用途。細菌感染佔據市場主導地位，2024 年佔 65.5% 的佔有率。院內感染，例如肺炎、泌尿道感染和血流感染仍然是令人擔憂的問題，特別是由革蘭氏陰性病原體如銅綠假單胞菌和肺炎克雷伯菌引起的感染。這些持續存在的挑戰推動了對胺基醣苷類抗生素作為可靠治療藥物的需求。

受細菌感染高發性和先進的醫療保健基礎設施的推動，美國胺基醣苷類抗生素市場價值在 2024 年將達到 7.267 億美元。診斷能力的提升使得有針對性的治療策略成為可能，促進了胺基醣苷類抗生素的精準有效使用。隨著細菌感染的盛行率持續上升，預計這些因素將在未來幾年維持該地區市場的成長勢頭。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 細菌感染發生率上升
    • 增加外科手術
    • 提高對抗菌素抗藥性的認知
    • 聯合治療的技術進步
  • 產業陷阱與挑戰
    • 替代療法的可用性
    • 嚴格的監管要求
• 成長潛力分析
• 監管格局
• 管道分析
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第 5 章：市場估計與預測：按產品，2021 年至 2034 年

• 主要趨勢
• 新黴素
• 妥布黴素
• 慶大霉素
• 阿米卡星
• 巴龍黴素
• 鏈黴素
• 其他產品

第 6 章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 細菌感染
  • 呼吸道感染
  • 皮膚和軟組織感染
  • 骨感染
  • 泌尿道感染 (UTI)
• 結核
• 其他應用

第 7 章：市場估計與預測：按管理路線，2021 年至 2034 年

• 主要趨勢
• 注射劑
• 口服
• 主題
• 眼科

第 8 章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院和診所
• 研究和學術機構
• 家庭護理設置
• 其他最終用戶

第 9 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Aurobindo Pharma
• Bausch Health Companies
• Cipla
• Fresenius Kabi
• Kremoint Pharma (Bliss GVS Pharma)
• Meiji Seika Pharma (Meiji Holdings)
• Novartis
• Perrigo Company
• Pfizer
• Sun Pharmaceutical Industries
• Sanofi
• Teva Pharmaceuticals

The Global Aminoglycosides Market was valued at USD 1.9 billion in 2024 and is poised to grow at a CAGR of 4% from 2025 to 2034. Aminoglycosides are renowned for their robust efficacy against Gram-negative bacteria, making them indispensable in the treatment of various infectious diseases. Their widespread use in addressing conditions such as urinary tract infections, pneumonia, and sepsis underscores their vital role in modern healthcare. These antibiotics are a cornerstone in combating bacterial infections, particularly in scenarios where other treatments may falter. Their versatility, in line with the rising prevalence of antimicrobial resistance, has further cemented their demand in global markets.

Governments worldwide contribute significantly to the growth of the aminoglycosides market by incorporating these essential antibiotics into subsidized healthcare systems and national programs. This not only boosts accessibility but also ensures their availability for managing a broad spectrum of infectious diseases. In addition, the development and adoption of advanced formulations, such as inhalation solutions for intravenous administration, have expanded their application in treating bronchial diseases, amplifying the demand for aminoglycosides.

The market is segmented by product into neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, and other products. In 2024, gentamicin emerged as the leading segment with a market valuation of USD 541.6 million. The increasing prevalence of drug-resistant bacterial infections has heightened the reliance on potent antibiotics like gentamicin. As antimicrobial resistance continues to challenge the global healthcare landscape, gentamicin's efficacy has made it a preferred choice among healthcare professionals.

From an application standpoint, the aminoglycosides market is categorized into bacterial infections, tuberculosis, and other uses. Bacterial infections dominated the market, accounting for a 65.5% share in 2024. This category encompasses respiratory infections, skin and soft tissue infections, bone infections, and urinary tract infections. Hospital-acquired infections, such as pneumonia, urinary tract infections, and bloodstream infections, remain significant concerns, particularly those caused by Gram-negative pathogens like Pseudomonas aeruginosa and Klebsiella pneumoniae. These persistent challenges drive the demand for aminoglycosides as reliable therapeutic agents.

The United States aminoglycosides market was valued at USD 726.7 million in 2024, driven by a high incidence of bacterial infections and advanced healthcare infrastructure. Improved diagnostic capabilities have enabled targeted treatment strategies, fostering the precise and effective use of aminoglycosides. As bacterial infections continue to rise in prevalence, these factors are expected to sustain market growth momentum in the region over the coming years.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of bacterial infection
    • 3.2.1.2 Increasing surgical procedures
    • 3.2.1.3 Increasing awareness of antimicrobial resistance
    • 3.2.1.4 Technological advancement in combination therapies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Availability of alternative therapies
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Neomycin
• 5.3 Tobramycin
• 5.4 Gentamicin
• 5.5 Amikacin
• 5.6 Paromomycin
• 5.7 Streptomycin
• 5.8 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Bacterial infection
  • 6.2.1 Respiratory infections
  • 6.2.2 Skin and soft tissue infections
  • 6.2.3 Bone infections
  • 6.2.4 Urinary Tract Infections (UTIs)
• 6.3 Tuberculosis
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Injectable
• 7.3 Oral
• 7.4 Topical
• 7.5 Ophthalmic

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Research and academic institutes
• 8.4 Homecare settings
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Aurobindo Pharma
• 10.2 Bausch Health Companies
• 10.3 Cipla
• 10.4 Fresenius Kabi
• 10.5 Kremoint Pharma (Bliss GVS Pharma)
• 10.6 Meiji Seika Pharma (Meiji Holdings)
• 10.7 Novartis
• 10.8 Perrigo Company
• 10.9 Pfizer
• 10.10 Sun Pharmaceutical Industries
• 10.11 Sanofi
• 10.12 Teva Pharmaceuticals